Venous thromboembolism: pathophysiology and clinical presentation.

Area of Science:

• Medicine
• Pharmacology
• Public Health

Background:

• Venous thromboembolism (VTE), encompassing deep venous thrombosis (DVT) and pulmonary embolism (PE), is a prevalent and life-threatening condition.
• An estimated 2 million Americans develop DVT annually, with approximately 100,000 deaths each year, highlighting a critical public health concern.
• VTE leads to significant short- and long-term morbidity, including recurrent VTE and postthrombotic syndrome (PTS), alongside substantial economic burdens.

Purpose of the Study:

• To discuss strategies for identifying and stratifying patients at risk for VTE.
• To review current guidelines for VTE prevention.
• To emphasize the role of health-system pharmacists in mitigating VTE risks.

Main Methods:

• The abstract discusses existing literature and clinical guidelines regarding VTE.
• It focuses on risk assessment, patient stratification, and prophylaxis strategies.
• The role of pharmacists in implementing preventive measures is highlighted.

Main Results:

• VTE is associated with high mortality rates, even with available treatments.
• Long-term consequences like PTS and recurrent VTE contribute to ongoing patient disability and healthcare costs.
• Routine prophylaxis is justified due to VTE's prevalence, asymptomatic nature, morbidity, mortality, and cost.

Conclusions:

• A systematic and proactive approach to VTE risk assessment and prophylaxis is essential.
• Health-system pharmacists play a vital role in identifying at-risk patients and ensuring appropriate preventive measures.
• Implementing effective VTE prevention strategies can significantly reduce incidence, morbidity, mortality, and associated costs.